Can targeted sedation help patients breathe easier on oxygen therapy?

NCT ID NCT07679932

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study looks at how two sedative drugs, dexmedetomidine and remifentanil, affect breathing effort in patients with acute hypoxemic respiratory failure who are receiving high-flow nasal oxygen. Researchers will measure changes in inspiratory effort and symptoms like shortness of breath and discomfort. The goal is to understand if tailored sedation can improve breathing patterns in these patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dexmedetomidine and remifentanil
What this could lead to
If successful, this could help doctors better manage sedation to ease breathing effort in patients with respiratory failure.
What could go wrong
This is a small, observational study with only 40 participants, so results may not apply to all patients. The drugs may cause side effects like low blood pressure or slow breathing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE HYPOXEMIC RESPIRATORY FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fondazione Policlinico Universitario A.Gemelli IRCCS

    Roma, RM, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.